个人简历

孙立博士，副研究员，硕士生导师。2003年获中国药科大学药理学专业硕士学位；2010年获中国药科大学药理学专业博士学位；2013年获国家留学基金委资助赴美留学。专业方向为肿瘤药理学，研究内容包括肿瘤微环境对肿瘤转移相关机制研究、抗肿瘤药物筛选以及抗肿瘤药物评价。主持参与多项国家自然科学基金项目、863项目等国家级纵向课题；发表SCI论文40余篇。

研究领域

肿瘤药理学

近期论文

1. Hou X., Du H, Yang R, Qi J, Huang Y, Feng S., Wu Y, Yuan S., Sun L. The antitumor activity screening of chemical constituents from Camellia nitidissima Chi. International Journal of Molecular Medicine.2018 May; 41(5):2793-2801. doi: 10.3892/ijmm.2018. 3502.
2. Hou X, Du H, Quan X, Shi L, Zhang Q, Wu Y, Liu Y, Xiao J, Li Y, Lu L, Ai X, Zhan M, Yuan S, Sun L. Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.Front Pharmacol. 2018 Feb 8; 9:21. doi: 10.3389/fphar.2018.00021. eCollection 2018.
3.Du H, Liu Y, Chen X, Yu X, Hou X, Li H, Zhan M, Lin S, Lu L, Yuan S, Sun L. DT-13 synergistically potentiates the sensitivity of gastric cancer cells to topotecan via cell cycle arrest in vitro and in vivo. European journal of pharmacology.2018 Jan 5; 818:124-131. doi: 10.1016/j.ejphar.2017.10.014.
4.Khan GJ, Gao Y, Gu M, Wang L, Khan S, Naeem F, Yousef BA, Roy D, Semukunzi H, Yuan S, Sun L. TGF-beta1 Causes EMT by regulating N-Acetyl Glucosaminyl Transferases via Downregulation of Non Muscle Myosin II-A through JNK/P38/PI3K pathway in lung cancer. Current cancer drug targets. 2018; 18(2): 209-219. doi: 10.2174/ 1568009617666170807120304.
5. Khan GJ, Rizwan M, Abbas M, Naveed M, Boyang Y, Naeem MA, Khan S, Yuan S, Baig MMFA, Sun L. Pharmacological effects and potential therapeutic targets of DT-13.
Biomedicine & pharmacotherapy. 2018 Jan; 97:255-263. doi: 10.1016 /j.biopha. 2017.10.101.
6.Lin S, Li H, Yu J, Zhang L, Yan M, Li H, Li X, Yuan S, Sun L: Inhibition of EGFR Signaling by N-cyclohexyl-2-(1-(phenylsulfonyl) piperidin-4-yl) acetamide. Anti-cancer agents in medicinal chemistry.2017 Nov 24; 17(11): 1500-1507. doi: 10.2174/ 18715206 17666170327125251.
7.Du H, Chen Y, Hou X, Huang Y, Wei X, Yu X, Feng S, Wu Y, Zhan M, Shi X, Lin S, Lu L, Yuan S, Sun L. PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC. Cell Death & Disease.2017 Oct 26;8(10): e3143. doi: 10.1038/cddis. 2017. 553.
8.Li MH, Du HZ, Kong GJ, Liu LB, Li XX, Lin SS, Jia AQ, Yuan ST, Sun L, Wang JS: Nuclear Magnetic Resonance-Based Metabolomics Approach to Evaluate the Prevention Effect of Camellia nitidissima Chi on Colitis-Associated Carcinogenesis. Frontiers in Pharmacology.2017 Jul 11;8:447. doi: 10.3389/fphar.2017.00447.
9.Du H, Pang M, Hou X, Yuan S, Sun L. PLOD2 in cancer research. Biomedicine & Pharmacotherapy. 2017 Jun; 90:670-676. doi: 10.1016/j.biopha.2017.04.023.
10.Li H, Sun L, Li H, Lv X, Semukunzi H, Li R, Yu J, Yuan S, Lin S: DT-13 synergistically enhanced vinorelbine-mediated mitotic arrest through inhibition of FOXM1-BICD2 axis in non-small-cell lung cancer cells. Cell Death & Disease.2017 May; 89:1277-1285. doi: 10.1016/j.biopha.2017.02.104.
11.Li H, Sun L, Li H, Lv X, Semukunzi H, Li R, Yu J, Yuan S, Lin S: DT-13, a saponin monomer 13 of the Dwarf lilyturf tuber, synergized with vinorelbine to induce mitotic arrest via activation of ERK signaling pathway in NCI-H1299 cells. Biomedicine & Pharmacotherapy.2017 May; 89:1277-1285. doi: 10.1016/j.biopha.2017.02.104.
12.Roy D, Sheng GY, Herve S, Carvalho E, Mahanty A, Yuan S, Sun L: Interplay between cancer cell cycle and metabolism: Challenges, targets and therapeutic opportunities. Biomedicine & Pharmacotherapy.2017 May; 89:288-296. doi: 10.1016/j.biopha.2017. 01.019.
13.Semukunzi H, Roy D, Li H, Khan GJ, Lyu X, Yuan S, Lin S: IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1 alpha. Biomedicine & Pharmacotherapy.2017 May; 89:805-811. doi: 10.1016/ j.biopha. 2017.02.083.
14. Yu X, Yang Q, Lin S, Yuan S, Sun L: Synergistic combination of YS-1 and adriamycin inhibits human renal cancer through ERK1/2 signaling pathway in vitro and in vivo. Oncology Reports. 2017 Mar; 37(3):1756-1764. doi: 10.3892/or.2017.5373.
15. Yu XW, Lin S, Du HZ, Zhao RP, Feng SY, Yu BY, Zhang LY, Li RM, Qian CM, Luo XJ, Yuan ST, Sun L. Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of egf receptor in vitro and in vivo. Oncotarget. 2016 Apr 20. doi: 10.18632/oncotarget.8843.
16. Li H, Sun L, de Carvalho EL, Li X, Lv X, Khan GJ, Semukunzi H, Yuan S, Lin S. DT-13, a saponin monomer of dwarf lilyturf tuber, induces autophagy and potentiates anti-cancer effect of nutrient deprivation. Eur J Pharmacol. 2016; 781: 164-72.
17. Du H, Huang Y, Hou XYu X, Lin S, Wei X, Li R, Khan GJ, Yuan S, Sun L. DT-13 inhibits cancer cell migration by regulating NMIIA indirectly in the tumor microenvironment. Oncol Rep. 2016 Aug; 36(2):721-8. doi: 10.3892/or.2016.4890.
18. Wei XH, Lin SS, Liu Y, Zhao RP, Khan GJ, Du HZ, Mao TT, Yu BY, Li RM, Yuan ST, Sun L. DT-13 attenuates human lung cancer metastasis via regulating NMIIA activity under hypoxia condition. Oncol Rep. 2016 Aug; 36(2):991-9. doi: 10.3892/or.2016.4879. Epub 2016 Jun 16.
19. Yu X, Zhao R, Lin S, Bai XZhang L, Yuan S, Sun L. CXCL16 induces angiogenesis in autocrine signaling pathway involving hypoxia-inducible factor 1α in human umbilical vein endothelial cells. Oncol Rep. 2016 Mar; 35(3):1557-65.
20. Pankova D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, Sun L, Gill BJ, Vadakkan TJ, Kim MP, Ahn YH, Roybal JD, Liu X, Parra Cuentas ER, Rodriguez J, Wistuba II, Creighton CJ, Gibbons DL, Hicks JM, Dickinson ME, West JL, Grande-Allen KJ, Hanash SM, Yamauchi M, Kurie JM, Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma.Mol Cancer Res. 2016 Mar; 14(3):287-95. doi: 10.1158/1541-7786.MCR-15-0307.
21. Chen Y, Terajima M, Yang Y, Sun L, Ahn YH, Pankova D, Puperi DS, Watanabe T, Kim MP, Blackmon SH, Rodriguez J, Liu H, Behrens C, Wistuba II, Minelli R, Scott KL, Sanchez-Adams J, Guilak F, Pati D, Thilaganathan N, Burns AR, Creighton CJ, Martinez ED, Zal T, Grande-Allen KJ, Yamauchi M, Kurie JM. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest. 2015 Feb 9. pii: 74725. doi: 10.1172/JCI74725.